CAMBRIDGE, Mass.--(BUSINESS WIRE)--
BIND Biosciences, a clinical-stage biopharmaceutical company developing a new class of highly selective targeted and programmable therapeutics called AccurinsTM, announced today that the United States Patent and Trademark Office has recently issued five U.S. patents to the company. The patents cover BIND-014,the companys lead Accurin product candidate for solid cancer tumors, and its Medicinal NanoengineeringTM platform which enables the design, engineering and manufacturing of Accurins with unprecedented control over drug properties to maximize trafficking to disease sites.
The newly-issued patents include:
The issuance of these five patents acknowledges the innovative nature of our platform and products, as well as the proprietary methods we use to produce them. We expect additional patent issuances over the coming months continuing to further bolster this broad and growing patent estate, said Scott Minick, CEO of BIND. We are highly encouraged by the real world impact of our innovative technology embodied in BIND-014, our lead Accurin product candidate which is showing promising clinical results for solid tumors.
About BIND Biosciences
BIND Biosciences is a clinical-stage biopharmaceutical company developing a new class of highly selective targeted and programmable therapeutics called AccurinsTM. BINDs Medicinal NanoengineeringTM platform enables the design, engineering and manufacturing of Accurins with unprecedented control over drug properties to maximize trafficking to disease sites, dramatically enhancing efficacy while minimizing toxicities.
BIND is developing a pipeline of novel Accurins that hold extraordinary potential to become best-in-class drugs and improve patient outcomes in the areas of oncology, inflammatory diseases and cardiovascular disorders. BIND's lead product candidate, BIND-014, is currently in Phase 1 clinical testing in cancer patients and is designed to selectively target a surface protein upregulated in a broad range of solid tumors. BIND also develops Accurins in collaboration with pharmaceutical and biotechnology partners to enable promising pipeline candidates to achieve their full potential and to utilize selective targeting to transform the performance of important existing drug products.
BIND is backed by leading investors, Polaris Venture Partners, Flagship Ventures, ARCH Venture Partners, NanoDimension, DHK Investments, EndeavourVision and Rusnano. BIND was founded on proprietary technology from the laboratories of two leaders in the field of nanomedicine, Professors Robert Langer, David H. Koch Institute Professor of the Massachusetts Institute of Technology (MIT) and Omid Farokhzad, Associate Professor of Harvard Medical School. For more information, please visit the company's web site at http://www.bindbio.com.
The rest is here:
BIND Is Granted Five U.S. Patents Covering BIND-014 and Accurin™ Platform